Results 271 to 280 of about 198,039 (308)

Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient.

, 2020
Julie Vandepapeliere, J Siplet, Louis Libbrecht, Hélène Dano, Jean‐François Baurain, Tom G. Moreels   +5 more
openalex   +1 more source

Elucidation of Proteoforms of Chinese Hamster Ovary (CHO) Phospholipase B‐Like 2 (PLBL2) Captured From a Monoclonal Antibody

Biotechnology and Bioengineering, Volume 123, Issue 2, Page 406-419, February 2026.
A platform approach to the affinity capture and enrichment of host cell proteins to enable their subsequent deep characterization and elucidation of variants or proteoforms (e.g., molecular size variants, charge variants, glycoforms, etc.). ABSTRACT Removing host cell proteins (HCPs) during biotherapeutic manufacturing is essential to ensure patient ...
Michael E. Dolan, Lei (Leo) Wang, Alexander Tedeschi, Yan Wang, Christopher Barton, Sheldon F. Oppenheim, Zhaohui Sunny Zhou   +6 more
wiley   +1 more source

Successful Combination Therapy With Lenvatinib Plus Pembrolizumab for Rare Case of Advanced Renal Cell Carcinoma With Ocular Adnexal Metastasis. [PDF]

Cancer Rep (Hoboken)
Mitsui Y, Uetani M, Yamabe F, Kobayashi H, Mitsuda A, Tochigi N, Nakajima K.   +6 more
europepmc   +1 more source

Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer

Cancer Innovation, Volume 5, Issue 1, February 2026.
Potential biomarkers for the development of targeted radionuclide therapy that can be employed in the treatment of breast cancer have been summarised in the review. They include receptor markers of ER, PR and HER2, as well as other markers of Trop2, PD‐1, EGFR, GRPR and PSMA.
Yujing Tan, Cheng Zeng, Jiani Wang, Fei Ma   +3 more
wiley   +1 more source

Neoadjuvant Pembrolizumab Combined with Chemotherapy for Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinomas: A Single-center Retrospective Study. [PDF]

J Cancer
Geng X, Zhao Y, Wu Y, Ma X, Xia R, Xu X, Ren G.   +6 more
europepmc   +1 more source

An Anoikis Resistance Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Blockades in Gastric Cancer

Cancer Innovation, Volume 5, Issue 1, February 2026.
Gastric cancer (GC) has high global incidence and mortality, with most cases diagnosed at advanced stages. Immunotherapy, particularly immune checkpoint blockers (ICBs), has shown promise, but not all patients benefit. This study applied consensus clustering based on anoikis‐related genes (ANRGs) to classify GC into two subclusters.
Xing Cai, Jinru Yang, Fangyuan Zhang, Fuwang Xu, Yuan Fang, Zongbi Yi   +5 more
wiley   +1 more source

Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study. [PDF]

Sci Rep
Kato T, Nakai Y, Sato M, Takao T, Iwanishi T, Toyoda S, Osaki H, Tsujihata M, Okada K, Kakimoto K, Horitani H, Ono Y, Nishimura K, Takada S, Fujita K, Takayama H, Miyake O, Nakayama M, Ishizuya Y, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Nonomura N.   +23 more
europepmc   +1 more source

Retrospective analysis of cutaneous immune‐related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA‐B*51:01 allele

Cancer, Volume 132, Issue 3, 1 February 2026.
ABSTRACT Background While immune checkpoint inhibitors (ICIs) have shown significant efficacy, a common side effect is cutaneous immune‐related adverse events (irAEs). This study focuses on exploring the association between specific human leukocyte antigen (HLA) alleles and the development of cutaneous irAEs in melanoma patients undergoing ICI ...
Mckenzie DiLeo, Samantha Oglesby, Cheuk Hong Leung, Kristen E. Pauken, Sahira Farooq, Lauren E. Haydu, Shelby L. Kubicki, Rebeca Martinez, Macartney Welborn, Sana Zahiruddin, Jun Zou, Kai Cao, Anisha B. Patel   +12 more
wiley   +1 more source

Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS. [PDF]

Front Pharmacol
Ma S.
europepmc   +1 more source